Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings ...

Eli Lilly’s profit doubled in the fourth ... Mounjaro and Zepbound are part of a wave of diabetes and obesity medications known as GLP-1 receptor agonists that are soaring in popularity globally ...

Eli Lilly (NYSE:LLY) on Thursday reported its ... Meanwhile, sales from Type 2 diabetes medication Trulicity fell ~25% YoY to $1.3B amid competitive headwinds and lower prices.

Eli Lilly’s profit doubled in the fourth quarter as the Indianapolis-based drugmaker raked in revenue from diabetes and obesity drugs. Net income rose to $4.4 billion, or $4.88 a share ...